Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hisun In-Licenses China Rights to Celsion’s Cancer Drug for $100 Million

publication date: Jan 22, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Zhejiang Hisun Pharma has in-licensed China rights to ThermoDox®, a liver cancer drug developed by Celsion Corporation, in a deal that totals $100 million in upfront and milestone payments. Celsion is expected to announce results from a Phase III trial of the drug later this month. In May 2012, Celsion chose Hisun as its global manufacturer for ThermoDox. Celsion expects the deal to be worth “hundreds of million of dollars” over time in milestones and royalties, given the prevalence of liver cancer in China. More details....

Stock Symbols: (SHA: 600267) (NSDQ: CLSN)

Share this with colleagues:  

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...